HRP20220029T1 - Supstituirani derivati ksantina - Google Patents
Supstituirani derivati ksantina Download PDFInfo
- Publication number
- HRP20220029T1 HRP20220029T1 HRP20220029TT HRP20220029T HRP20220029T1 HR P20220029 T1 HRP20220029 T1 HR P20220029T1 HR P20220029T T HRP20220029T T HR P20220029TT HR P20220029 T HRP20220029 T HR P20220029T HR P20220029 T1 HRP20220029 T1 HR P20220029T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- compound according
- disorder
- disorders
- disease
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 5
- 208000000044 Amnesia Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000031091 Amnestic disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 230000006986 amnesia Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000025978 Athletic injury Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000000810 Separation Anxiety Diseases 0.000 claims 1
- 102000003621 TRPC5 Human genes 0.000 claims 1
- 101150042815 TRPC5 gene Proteins 0.000 claims 1
- 108010037150 Transient Receptor Potential Channels Proteins 0.000 claims 1
- 102000011753 Transient Receptor Potential Channels Human genes 0.000 claims 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 206010013461 dissociative amnesia Diseases 0.000 claims 1
- 208000018459 dissociative disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000005032 impulse control Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (13)
1. Spoj odabran iz skupine koja se sastoji od
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili
[image]
2. Spoj prema zahtjevu 1, odnosno
[image]
3. Spoj prema zahtjevu 1, odnosno
[image]
4. Spoj prema zahtjevu 1, odnosno
[image]
5. Spoj prema zahtjevu 1, odnosno
[image]
6. Spoj prema zahtjevu 1, odnosno
[image]
7. Spoj prema zahtjevu 1, odnosno
[image]
8. Spoj prema zahtjevu 1, odnosno
[image]
9. Farmaceutski prihvatljiva sol spoja prema bilo kojem od prethodnih zahtjeva.
10. Spoj prema bilo kojem od zahtjeva 1-8 ili farmaceutski prihvatljiva sol prema zahtjevu 9 za uporabu kao lijek.
11. Farmaceutski pripravak koji sadrži spoj prema bilo kojem od zahtjeva 1-8 ili farmaceutski prihvatljivu sol prema zahtjevu 9.
12. Spoj prema bilo kojem od zahtjeva 1-8 ili farmaceutski prihvatljiva sol prema zahtjevu 9 za uporabu u liječenju psihijatrijskog, neurološkog ili neurodegenerativnog stanja, pri čemu je inhibicija aktivnosti prolaznog receptorskog potencijalnog kationskog kanala TRPC5 terapeutska korist.
13. Spoj ili farmaceutski prihvatljiva sol za uporabu prema zahtjevu 12, naznačen time što je psihijatrijsko, neurološko ili neurodegenerativno stanje odabrano iz skupine koju čine bolesti povezane s nereguliranom emocionalnom obradom (npr. granični poremećaj osobnosti ili depresivni poremećaji poput velike depresije, velikog depresivnog poremećaja, psihijatrijska depresija, distimija i postporođajna depresija, te bipolarni poremećaji), anksioznost i poremećaji povezani sa strahom (npr. posttraumatski stresni poremećaj, panični poremećaj, agorafobija, socijalne fobije, generalizirani anksiozni poremećaj, panični poremećaj, socijalno anksiozni poremećaj, opsesivno kompulzivni poremećaj, i anksioznost separacije), poremećaji pamćenja (npr. Alzheimerova bolest, amnezija, afazija, ozljeda mozga, tumor na mozgu, sindrom kroničnog umora, Creutzfeldt-Jakobova bolest, disocijativna amnezija, fuga amnezija, Huntingtonova bolest, poremećaji učenja, poremećaji spavanja, poremećaj višestruke osobnosti, bol, posttraumatski stresni poremećaj, shizofrenija, sportske ozljede, moždani udar i Wernicke-Korsakoffov sindrom), poremećaji povezani s poremećenom kontrolom impulsa i ovisnosti, kao i Alzheimerova bolest, Parkinsonova bolest, Huntingtonova bolest, amiotrofična lateralna skleroza i drugi moždani poremećaji uzrokovani traumom uključujući starenje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17180721 | 2017-07-11 | ||
| PCT/EP2018/068366 WO2019011802A1 (en) | 2017-07-11 | 2018-07-06 | NEW SUBSTITUTED XANTHINE DERIVATIVES |
| EP18735588.8A EP3652176B1 (en) | 2017-07-11 | 2018-07-06 | Substituted xanthine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220029T1 true HRP20220029T1 (hr) | 2022-04-15 |
Family
ID=59325162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220029TT HRP20220029T1 (hr) | 2017-07-11 | 2018-07-06 | Supstituirani derivati ksantina |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10329292B2 (hr) |
| EP (1) | EP3652176B1 (hr) |
| JP (1) | JP7114702B2 (hr) |
| KR (1) | KR20200030048A (hr) |
| CN (1) | CN110997675B (hr) |
| AR (1) | AR112448A1 (hr) |
| AU (1) | AU2018299824B2 (hr) |
| BR (1) | BR112019025611A2 (hr) |
| CA (1) | CA3066922A1 (hr) |
| CL (1) | CL2020000056A1 (hr) |
| CO (1) | CO2019015102A2 (hr) |
| CY (1) | CY1125014T1 (hr) |
| DK (1) | DK3652176T3 (hr) |
| EA (1) | EA039526B1 (hr) |
| ES (1) | ES2903268T3 (hr) |
| HR (1) | HRP20220029T1 (hr) |
| HU (1) | HUE057600T2 (hr) |
| IL (1) | IL271799B (hr) |
| LT (1) | LT3652176T (hr) |
| MX (1) | MX2020000402A (hr) |
| PH (1) | PH12020500079A1 (hr) |
| PL (1) | PL3652176T3 (hr) |
| PT (1) | PT3652176T (hr) |
| RS (1) | RS62826B1 (hr) |
| SA (1) | SA519410851B1 (hr) |
| SG (1) | SG11201912168TA (hr) |
| SI (1) | SI3652176T1 (hr) |
| TW (1) | TWI801398B (hr) |
| UA (1) | UA124793C2 (hr) |
| WO (1) | WO2019011802A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019396499A1 (en) * | 2018-12-12 | 2021-05-27 | Boehringer Ingelheim International Gmbh | Substituted xanthine derivatives |
| WO2020120449A1 (en) * | 2018-12-12 | 2020-06-18 | Boehringer Ingelheim International Gmbh | Substituted xanthine derivatives |
| MX2022004049A (es) * | 2019-10-04 | 2022-07-11 | Goldfinch Bio Inc | Tratamiento basado en biomarcadores de la glomeruloesclerosis focal y segmentaria y de la enfermedad renal diabetica. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY133479A (en) * | 2001-02-24 | 2007-11-30 | Boehringer Ingelheim Pharma | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| AU2007274710A1 (en) * | 2006-07-14 | 2008-01-24 | Pfizer Products Inc. | Tartrate salt of (7S)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2R)-2-methylpiperazin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridine |
| US9359359B2 (en) * | 2013-03-15 | 2016-06-07 | Hydra Biosciences, Inc. | Substituted xanthines and methods of use thereof |
| TWI676626B (zh) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | 抑制瞬時受體電位ａ１離子通道 |
| JP6667093B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体 |
| EP3180342B1 (en) * | 2014-08-11 | 2019-06-26 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
| JP6559228B2 (ja) | 2014-09-17 | 2019-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物 |
-
2018
- 2018-07-06 KR KR1020207000260A patent/KR20200030048A/ko not_active Application Discontinuation
- 2018-07-06 PL PL18735588T patent/PL3652176T3/pl unknown
- 2018-07-06 DK DK18735588.8T patent/DK3652176T3/da active
- 2018-07-06 HR HRP20220029TT patent/HRP20220029T1/hr unknown
- 2018-07-06 BR BR112019025611-3A patent/BR112019025611A2/pt unknown
- 2018-07-06 AU AU2018299824A patent/AU2018299824B2/en active Active
- 2018-07-06 UA UAA202000735A patent/UA124793C2/uk unknown
- 2018-07-06 IL IL271799A patent/IL271799B/en unknown
- 2018-07-06 PT PT187355888T patent/PT3652176T/pt unknown
- 2018-07-06 CN CN201880045961.0A patent/CN110997675B/zh active Active
- 2018-07-06 JP JP2020523041A patent/JP7114702B2/ja active Active
- 2018-07-06 EP EP18735588.8A patent/EP3652176B1/en active Active
- 2018-07-06 LT LTEPPCT/EP2018/068366T patent/LT3652176T/lt unknown
- 2018-07-06 HU HUE18735588A patent/HUE057600T2/hu unknown
- 2018-07-06 CA CA3066922A patent/CA3066922A1/en active Pending
- 2018-07-06 RS RS20211577A patent/RS62826B1/sr unknown
- 2018-07-06 SG SG11201912168TA patent/SG11201912168TA/en unknown
- 2018-07-06 WO PCT/EP2018/068366 patent/WO2019011802A1/en unknown
- 2018-07-06 MX MX2020000402A patent/MX2020000402A/es unknown
- 2018-07-06 ES ES18735588T patent/ES2903268T3/es active Active
- 2018-07-06 EA EA202090270A patent/EA039526B1/ru unknown
- 2018-07-06 SI SI201830519T patent/SI3652176T1/sl unknown
- 2018-07-10 US US16/031,399 patent/US10329292B2/en active Active
- 2018-07-10 TW TW107123858A patent/TWI801398B/zh active
- 2018-07-11 AR ARP180101931 patent/AR112448A1/es unknown
-
2019
- 2019-12-18 SA SA519410851A patent/SA519410851B1/ar unknown
- 2019-12-30 CO CONC2019/0015102A patent/CO2019015102A2/es unknown
-
2020
- 2020-01-08 CL CL2020000056A patent/CL2020000056A1/es unknown
- 2020-01-10 PH PH12020500079A patent/PH12020500079A1/en unknown
-
2022
- 2022-01-12 CY CY20221100028T patent/CY1125014T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220029T1 (hr) | Supstituirani derivati ksantina | |
| BR112018000041A2 (pt) | Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl | |
| BR112019004243A2 (pt) | composto, composição farmacêutica, método para inibição de quinase do zíper de leucina dupla, método para tratamento de uma doença mediada por quinase do zíper de leucina dupla e método para obter um efeito em um paciente | |
| MX2019006645A (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| JP2019524822A5 (hr) | ||
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| EA201891374A1 (ru) | Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение | |
| ECSP056207A (es) | Derivados de 3-alquil y 3-alquenilazetidina sustituidos | |
| JP2007500757A5 (hr) | ||
| BR112018010564A2 (pt) | composições farmacêuticas compreendendo levodopa amida e usos das mesmas | |
| CA2864606C (en) | Methods of treating and preventing diseases and disorders of the central nervous system | |
| HRP20220223T1 (hr) | Biciklički inhibitori histon deacetilaze | |
| ECSP088477A (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos | |
| BR112018008056A2 (pt) | derivados de indolin-2-ona | |
| ATE457985T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| JP2020526591A5 (hr) | ||
| WO2018027037A3 (en) | Reelin compositions for treatment of neurological disorders | |
| WO2007135131A8 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| JP2017525776A5 (hr) | ||
| TR201905319T4 (tr) | Nevralji, ağrı, KOAH (Kronik, Obstruktif Akciğer Hastalığı) ve astım tedavisinde TRPM8-inhibitörleri olarak yararlı 2-aril-4-hidroksi-1,3-tiyazol türevleri. | |
| ATE471322T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| HRP20211340T1 (hr) | Terapijski agens za frontalnu lobarnu disfunkciju | |
| EP4069315A4 (en) | STABILIZATION OF RETROMER FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | |
| AR121118A1 (es) | Factores de transcripción de proteínas de dedos de zinc para reprimir la expresión de tau | |
| WO2020123977A3 (en) | Glial fibrillary acidic protein targeting immuno-and aptamer-based-therapy for neuroinjury, neurodegeneration, neuro-disease, and neuro-repair |